Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Progenics Pharmaceuticals Inc. (PGNX)

4.1   -0.425 (-9.39%) 11-27 12:26
Open: 4.6 Pre. Close: 4.525
High: 4.79 Low: 4.01
Volume: 34,928,367 Market Cap: 355M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.797 - 4.821 4.821 - 4.841
Low: 3.962 - 3.984 3.984 - 4.002
Close: 4.067 - 4.102 4.102 - 4.131

Technical analysis

as of: 2020-06-26 4:34:23 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 5.04     One year: 5.64
Support: Support1: 3.48    Support2: 2.90
Resistance: Resistance1: 4.31    Resistance2: 4.83
Pivot: 4.35
Moving Average: MA(5): 4.31     MA(20): 4.30
MA(100): 4.03     MA(250): 4.68
MACD: MACD(12,26): 0.09     Signal(9): 0.11
Stochastic oscillator: %K(14,3): 47.25     %D(3): 50.43
RSI: RSI(14): 47.86
52-week: High: 6.37  Low: 1.89  Change(%): -21.5
Average Vol(K): 3-Month: 128263  10-Days: 443006

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
PGNX has closed above bottom band by 20.7%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 22 Jun 2020
Lantheus Completes Merger with Progenics - Business Wire

Tue, 16 Jun 2020
Progenics Stockholders Approve Merger with Lantheus Nasdaq:PGNX - GlobeNewswire

Wed, 27 May 2020
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc. - PRNewswire

Fri, 08 May 2020
Progenics Class Action: Halper Sadeh LLP Announces Filing Of Shareholder Class Action Lawsuit Against Progenics Pharmaceuticals, Inc.; Investors Are Encouraged To Contact The Firm - PRNewswire

Thu, 07 May 2020
Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update - GlobeNewswire

Thu, 23 Apr 2020
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Progenics Pharmaceuticals, Inc. (PGNX) - PRNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 87
Shares Float (M) 68
% Held by Insiders 9.60
% Held by Institutions 76.10
Shares Short (K) 5,760
Shares Short P. Month (K) 5,530

Stock Financials

EPS -0.774
EPS Est This Year -0.900
EPS Est Next Year -0.360
Book Value (p.s.) 0.350
Profit Margin -180.28
Operating Margin -165.87
Return on Assets (ttm) -29.2
Return on Equity (ttm) -116.9
Qtrly Rev. Growth 45.9
Gross Profit (p.s.) 0.367
Sales Per Share 0.427
EBITDA (p.s.) -0.678
Qtrly Earnings Growth
Operating Cash Flow (M) -64
Levered Free Cash Flow (M) -54

Stock Valuations

PE Ratio -5.30
PEG Ratio
Price to Book value 11.71
Price to Sales 9.61
Price to Cash Flow -5.57

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.